Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded at StockNews.com

StockNews.com upgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a strong-buy rating in a research report released on Friday morning.

CPRX has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $35.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday. Bank of America reiterated a “buy” rating and set a $30.00 price target on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Truist Financial upped their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. Baird R W upgraded shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Monday, February 3rd. Finally, Stephens restated an “overweight” rating and set a $33.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Trading Up 5.7 %

Catalyst Pharmaceuticals stock opened at $22.89 on Friday. Catalyst Pharmaceuticals has a 52 week low of $14.47 and a 52 week high of $24.64. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of 19.40, a PEG ratio of 3.31 and a beta of 0.80. The company’s 50-day moving average price is $22.21 and its two-hundred day moving average price is $21.40.

Insiders Place Their Bets

In other news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. This trade represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 11.00% of the company’s stock.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CPRX. Steward Partners Investment Advisory LLC purchased a new stake in shares of Catalyst Pharmaceuticals in the fourth quarter valued at $27,000. Park Square Financial Group LLC acquired a new position in Catalyst Pharmaceuticals during the fourth quarter valued at $29,000. Farther Finance Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 125.1% in the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock worth $56,000 after acquiring an additional 1,495 shares in the last quarter. Larson Financial Group LLC grew its stake in Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 2,994 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $65,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.